



OVERVIEW OF THE RIGHTS ISSUE IN MAGNASENSE AB

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE, JAPAN, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD NOT BE IN COMPLIANCE WITH APPLICABLE REGULATIONS OR WOULD REQUIRE REGISTRATION OR SIMILAR MEASURES. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THE PRESS RELEASE.

Invitation to subscribe for Units to Fund Magnasense's Saliva-Based Diagnostics

Existing and new shareholders are invited to subscribe for units in Magnasense under the Rights Issue that is open between 24 April 2025 and 8 May 2025. This presents an opportunity to invest in saliva-based disease testing as an alternative to blood testing. Shareholders who choose not to participate in the Rights Issue will be diluted. The funds raised are essential for Magnasense's continued operations and advancing of the initial phase of the oral health project. If the company is unable to secure new capital, it could significantly impact its ability to continue operations.

Prospects for the future are exciting as proving that saliva-based testing is a viable alternative to blood testing will allow Magnasense to use its technology, knowledge and experience to test for other diseases and in doing so establish a significant revenue stream from licensing its technology and providing bespoke test reports.

Historical Research and Product Development

Since its formation in 2019, Magnasense has established a number of subsidiary companies in Sweden, the US, Finland and the UK to conduct research into the testing for various diseases, including Covid-19. The aim has been to develop products for licence to third-party manufacturers, distributors, and users to generate royalty-based income. A recent challenge has been funding the various areas of research undertaken by different subsidiaries.

Historical Fundraising

To date, Magnasense has funded its research through a combination of rights issues, loans, corporate research grants, and government support. Recently, financing has been provided by Atlas Special Opportunities, LLC, through a secured convertible bond and loan facility that allows for the conversion of debt into equity. This financing has played an important role in funding ongoing research, and the executed addendum strengthens the company's capital structure and facilitates broader financing efforts.



Background to the Rights Issue

The priorities of this Rights Issue have been to restructure the agreements with Atlas, restore shareholder confidence, and secure sufficient funding for ongoing research and product development - eliminating the need for additional capital raising, provided the rights issue is fully subscribed and the subsequent exercise of warrants is successful.

Focus on Saliva-Based Testing and its Future Revenue Prospects

The UK subsidiary of Magnasense, Aegirbio UK has become a leading developer of saliva-based testing for disease as an alternative to blood testing. This offers a non-invasive, cost-effective, and highly convenient way to detect and monitor a wide range of health conditions, from diseases to systemic issues like diabetes, neurological -and heart disease. The test results will be used to provide bespoke reports and will be held in a central database of anonymised data that can be used for identifying other diseases and recommending treatment plans. Magnasense believes Aegirbio UK offers the best prospects for early revenue as well as significant potential for future revenue streams.

While further work is needed to refine the saliva collection device, reader, and test—along with developing the Cloud solution required for generating reports and building a central database for potential AI applications—the first solution will be targeted at the professional market, including general practitioners, dentists, dental hygienists, and pharmacy-based testing. The second goal is to create a device suitable for home use, empowering individuals to take control of their own health.

The initial focus will be on testing for Periodontitis, with plans to engage major manufacturers and distributors as third-party partners. Collaborating with these partners will help reduce costs and risks, while also offering potential for early revenue through three main channels: licensing the technology, leveraging the data, and providing test reports.

The information memorandum with full details of the rights issue and subscription forms are available online via: www.magnasense.com and via: www.eminova.se.

For more information contact:

Marco Witteveen, CEO

E-mail: ir@magnasense.com

The Company's Certified Adviser is Eminova Fondkommission AB | adviser@eminova.se

IMPORTANT INFORMATION

The publication, release or distribution of this press release in certain jurisdictions may be restricted by law and persons in the jurisdictions in which this press release has been published or distributed should inform themselves about and observe any such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction. This press release



does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities issued by the Company in any jurisdiction in which such offer or solicitation would be unlawful.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the “**Prospectus Regulation**”) and has not been approved or reviewed by any regulatory authority in any jurisdiction.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an applicable exemption from registration under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”), or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Canada, Australia, Hong Kong, New Zealand, South Africa, South Korea, Switzerland, Singapore, Japan, Russia, Belarus or any other jurisdiction where such announcement, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities legislation.

In the United Kingdom, this document, and any other materials in relation to the securities referred to herein, is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “**Order**”) or (ii) high net worth persons as referred to in Article 49(2)(a) to (d) of the Order (all such persons are collectively referred to as “relevant persons”). Any investment or investment activity to which this communication relates is available in the United Kingdom only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons should not take any action based on this press release and should not or act or rely on it.

This press release does not identify or purport to identify any risks (direct or indirect) that may be associated with an investment in new shares. This press release does not constitute an invitation to underwrite, subscribe or otherwise acquire or transfer securities in any jurisdiction. This press release does not constitute a recommendation for any investor's decision regarding the Rights Issue. Each investor or potential investor should conduct its own investigation, analysis and evaluation of the business and information described in this press release and any publicly



available information. The price and value of the securities may go down as well as up and past performance is not a guide to future results. Neither the contents of the Company's website nor any other website accessible through hyperlinks on the Company's website are incorporated into or form part of this press release.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs or expectations regarding the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by the use of words such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "anticipates", "should", "could" and, in each case, the negatives thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialise or that they are accurate. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes could differ materially from those in the forward-looking statements for a variety of reasons. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by the forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements contained in this press release are accurate and any reader of this press release should not place undue reliance on the forward-looking statements contained in this press release. The information, opinions and forward-looking statements expressed or implied herein are made only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statement to reflect events that occur or circumstances that arise in relation to the content of this press release, except as required by law or the rules of Nasdaq First North Growth Market.

About Magnasense

Magnasense is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, Magnasense was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Magnasense's website www.magnasense.com.